Dept. of Surgical Oncology, Zydus Hospital, Ahmedabad, India.
Peritoneal Metastases Center, Kishiwada Tokushukai Hospital, Osaka, Japan.
Eur J Surg Oncol. 2019 Dec;45(12):2398-2404. doi: 10.1016/j.ejso.2019.07.019. Epub 2019 Jul 16.
The grade/histological subtype is one of the most important prognostic markers in patients undergoing cytoreductive surgery (CRS). Our aim was to study other potential prognostic information that can be derived from the pathological evaluation of CRS specimens and provide a broad outline for evaluation of these.
This prospective study (July to December 2018) included all patients undergoing cytoreductive surgery (CRS). A protocol for pathological evaluation was laid down which was based on existing practices at the participating centers and included evaluation of the pathological PCI, regional node involvement, response to chemotherapy, morphology of peritoneal metastases (PM) and distribution in the peritoneal cavity.
In 191 patients undergoing CRS at 4 centers, the pathological and surgical PCI differed in over 75%. Nodes in relation to peritoneal disease were positive in 13.6%. Disease in normal peritoneum adjacent to tumor nodules was seen in >50% patients with ovarian cancer and mucinous apppendiceal tumors. 23.8% of evaluated colorectal PM patients had a complete response and 25.0% ovarian cancer patients had a near complete pathological response to chemotherapy.
Pathological evaluation of extent and distribution of peritoneal disease differs from the surgical evaluation in majority of the patients. Lymph node involvement in relation of peritoneal disease is common. The morphological presentation of PM in ovarian cancer and mucinous appendiceal tumors merits evaluation of more extensive resections in these patients. Standardized methods of synoptic reporting of CRS specimens could help capture vital prognostic information that may in future influence how these patients are treated.
在接受细胞减灭术(CRS)的患者中,分级/组织学亚型是最重要的预后标志物之一。我们的目的是研究从 CRS 标本的病理评估中得出的其他潜在预后信息,并为评估这些信息提供广泛的概述。
本前瞻性研究(2018 年 7 月至 12 月)纳入了所有接受细胞减灭术(CRS)的患者。制定了病理评估方案,该方案基于参与中心的现有实践,并包括评估病理 PCI、区域淋巴结受累、对化疗的反应、腹膜转移(PM)的形态和在腹膜腔中的分布。
在 4 个中心的 191 名接受 CRS 的患者中,病理和手术 PCI 的差异超过 75%。与腹膜疾病相关的淋巴结阳性率为 13.6%。在卵巢癌和黏液性阑尾肿瘤患者中,超过 50%的患者可见肿瘤结节附近正常腹膜中的疾病。评估的结直肠 PM 患者中,有 23.8%完全缓解,卵巢癌患者中有 25.0%对化疗有接近完全的病理缓解。
大多数患者的腹膜疾病的范围和分布的病理评估与手术评估不同。与腹膜疾病相关的淋巴结受累很常见。卵巢癌和黏液性阑尾肿瘤中 PM 的形态表现值得评估这些患者是否需要更广泛的切除。CRS 标本的综合报告标准化方法可以帮助捕捉重要的预后信息,这些信息可能会影响未来如何治疗这些患者。